Oral Presentation Australasian Melanoma Conference 2026

Multidisciplinary team perspectives on specialist melanoma nurse role integration and system-level impact across a national program (#15)

Shahn Coburn 1 , Rebecca Johnson 1 2 , Mei Krishnasamy 3 4 , Grant McArthur 3 4 5 , Alexander M Menzies 1 2 6 7 , Megan Lyle 8 , Thomas E Pennington 1 2 6 9 , Kate White 2 9 , Angela Hong 1 2 9 , Georgina V Long 1 2 6 7 , Maria Gonzalez 1
  1. Melanoma Institute Australia, Wollstonecraft, NSW
  2. The University of Sydney, Sydney, NSW
  3. University of Melbourne, Melbourne, VIC
  4. VCCC Alliance, Melbourne, VIC
  5. Peter MacCallum Cancer Centre, Melbourne, NSW
  6. Mater Hospital, North Sydney, NSW
  7. Royal North Shore Hospital, St Leonards, NSW
  8. Cairns Hinter Health Service, Cairns, QLD
  9. Royal Prince Alfred Hospital, Camperdown, NSW

Background: The National Melanoma Nurses Program (NMNP), a federally funded initiative 2023-2026, integrated 30 Specialist Melanoma Nurses (SMNs) across 37 sites nationally as embedded members of melanoma multidisciplinary teams (MDT). SMNs are advanced practice nurses providing specialised care to patients with high-risk or advanced melanoma. This study aimed to assess MDT perceptions of SMN role integration, and system and team-level impacts.

Methods: A cross-sectional online survey was conducted (September-November 2025) as part of a broader mixed-methods program evaluation. The purpose-built survey of 8 closed-ended questions, with open-ended justification, explored nursing role integration and perceived system and team-level impacts of specialist nursing care. MDT members with a direct working relationship with a SMN were purposively sampled across 37 settings. Descriptive statistics were applied to closed-ended items; content analysis to open-ended responses.

Results: 84 MDT members responded across nursing (n=37, 44%), medical oncology (n=11, 13%), allied health (n=9, 11%), and surgery (n=8, 10%), with remaining respondents from administration, management, and other departments (n=19, 22%). 79% of participants (n=66) interacted with their site’s SMN at least weekly. Team and system-level impact was positive, with 81 (96%) participants agreeing that a service gap at their site had been addressed and that the melanoma care team functioned more effectively following integration of the SMN. Most (n=81, 96%) agreed or strongly agreed that the SMN was well integrated into the MDT. Across team and system-level outcomes, most respondents perceived improvement after SMN commencement: quality of care coordination was rated higher by 69 (82%), with improved management of neoadjuvant treatment pathways most frequently cited in open-ended responses. Timely access to care was rated higher by 62 (74%), referral to allied health by 58 (69%), adherence to treatment plans by 55 (65%) and toxicity management pathways by 52 (62%).

Conclusion: MDT members reported that SMNs enhance team and system-level functioning regarding care coordination, toxicity management, treatment adherence, and access to care. These findings demonstrate the contribution of SMN roles to effective functioning of MDT-led care amid increasingly complex treatment pathways. Future research should focus on robust evaluation of SMN roles to patient-reported experience and outcomes of care.